open-field, elevated-plus maze and light-dark tests compared to wild-type (WT) littermates (Supplementary Figures 1a-g ). In tailsuspension and forced-swimming tests, which are reliable predictors of antidepressant potential, 5 vehicle-treated adult KO or heterozygous (HET) mice showed significantly reduced levels of immobility compared to WT animals (Figures 1c and d and Supplementary Figures 1h and i) . Notably, fluoxetine treatment did not cause a further decrease in immobility in KO and HET mice (Figures 1c and d) , indicating that sFRP3 downregulation alone is sufficient to induce antidepression-like behavioral responses.
Responses of patients with major depression to antidepressant treatment can be influenced by genetic variations. 6 In parallel to animal studies, we conducted a pharmacogenetic association study of the human sFRP3 gene (FRZB) in a cohort of 541 Caucasian patients with major depression, 7 with latency to antidepressant response and partial response (50% or 25% decrease in symptom severity, respectively). We assessed 19 SNPs spanning 10 kb from 3 0 to 5 0 of the FRZB locus ( Supplementary Figures 2 and 3a) . All SNPs were in HardyWeinberg equilibrium. While no SNPs showed significant association with latency to response, two SNPs located 3 0 of the gene (rs11902959/P ¼ 0.0028; rs1530056/P ¼ 0.0044) and one SNP in the 3 0 -untranslated region (rs4666865/P ¼ 0.0097) exhibited significant association with latency to partial response, with rs11902959 and rs1530056 surviving multiple testing corrections (P ¼ 0.038) and rs4666865 showing a trend-level association (P ¼ 0.055; Figures 1e-g and Supplementary Figure 2b) . All SNPs showed a gene-dose dependent effect (Figure 1f ). w 2 test revealed no difference in allele frequencies of these three SNPs between patients with unipolar depression and healthy subjects 8 ( Supplementary Figure 3b) , excluding a potential contribution from a skewed allelic frequency in better or worse responding groups. These SNPs are in moderate to low linkage disequilibrium ( Figure 1e ) and appear to represent at least two distinct loci of association. To investigate the potential joint effects of these variants, we performed haplotype-based association tests. The rs11902959/rs1530056 haplotype gave an omnibus P-value of 0.0014, with a highly significant association of the CA haplotype (P ¼ 0.0016; frequency ¼ 8.9%) and TG haplotype (P ¼ 0.0051; frequency ¼ 48.3%). The rs1530056/rs4666865 haplotype also showed a significant overall association (P ¼ 0.028) and associations of the GG haplotype (P ¼ 0.0051; frequency ¼ 36.9%) and AA haplotype (P ¼ 0.0075; frequency ¼ 49.7%; Figure 1h ). To gain insight into the function of these SNP variants, we investigated a public database for SNP genotype statistical associations with transcript expression in human brains. 9 Interestingly, rs1530056 (P ¼ 0.04) and rs44666865 (P ¼ 0.02) showed significant association with FRZB expression and the major allele A predicted lower FRZB expression levels in both SNPs in a genedose dependent manner (Supplementary Figure 4) . This result corroborates pharmacogenetic association results in which the A allele in both SNPs was associated with a better response to antidepressant treatment. These convergent results from pharmacogenetic and SNP expression association analyses suggest that functionally relevant polymorphisms in FRZB contribute to antidepressant response in clinical cohorts, potentially via differential regulation of FRZB expression.
Despite being effective, antidepressant pharmacotherapy is hampered by the slow onset of clinically appreciable improvement and significant side effects. Recent studies have suggested Wnt signaling as a target for mood disorder treatment. 10 Our studies identify a novel function of sFRP3, a naturally secreted inhibitor of Wnt signaling, as an essential mediator of antidepressant actions in animal models, and reveal significant association of its polymorphisms with latency to antidepressant response in patients with depression. Targeting of sFRP3 may represent a novel therapeutic approach for depression treatment. The nonapeptide oxytocin (OT), dubbed by the media as the 'moral' or 'love' molecule, has a variety of pro-social effects across species. A relatively simple explanation for these complex effects is that OT alleviates anxiety, 1 thereby indirectly promoting trust, cooperation and other affiliative behaviors. 2, 3 Indeed, OT can reduce anxiety-like behavior in animals, via its neuromodulatory influence on the amygdala, a core hub mediating fear and anxiety.
CONFLICT OF INTEREST
4 Surprisingly, OT also promotes territoriality, aggression and other defensive behaviors toward out-group members, 2 complicating any straightforward interpretation of OT's socioemotional effects. Here, we show that OT does not reduce but rather increases defensive responding to unpredictable threat in humans, suggesting that OT enhances anxiety. A critical distinction has been recognized between two kinds of defensive states, sustained anxiety and phasic fear. 5 Although the former is elicited by ambiguity and uncertainty (that is, unpredictable threat), the latter is evoked by explicit threat cues (that is, predictable threat). 5 The hypothesis that OT differentially modulates defensive responses to unpredictable versus predictable threats directly follows evidence that OT released from the paraventricular nucleus of the hypothalamus facilitates excitatory signaling in the bed nucleus of the stria terminalis (BNST), 7, 8 a critical structure mediating defensive responses to unpredictable threats. 5 In addition, OT receptor density varies by subdivision within the central nucleus of the rodent amygdala (CeA) 4, 6 and these subdivisions are differentially involved in defensive responses to predictable (fear) and unpredictable threats (anxiety). The medial CeA (mCeA) and lateral CeA (lCeA) are involved in fear and anxiety, 5 respectively, but only the lCeA is rich in OT receptors. 6 Finally, while in rodents endogenous OT reduces freezing to a fear conditioned cue, 8 systemic OT administration does not affect fear-potentiated startle to a threat cue. 9 Accordingly, we tested the possibility that OT may selectively increase defensive responding to unpredictable but not predictable threats using startle as a measure of fear and anxiety. 5 Methods are fully described in Supplementary Information (see also Schmitz and Grillon 10 ). We assayed startle reactivity, a wellestablished index of aversive state, 5 in three conditions (see Figure 1 ) no shock (N), 2) predictable shocks (P) administered only during threat cues (red circles in the figure), and unpredictable shocks (U) administered randomly. Using a double-blind randomized within-subjects design, we administered placebo, OT, the structurally-related neuropeptide arginine vasopressin (AVP), and placebo (PLC) to 43 subjects in three sessions.
Results are shown in the figure (see also Supplementary Information). Defensive responses to unpredictable shocks were significantly increased by OT compared with both PLC (F(1,42) 
This is the first evidence that OT can be anxiogenic in humans. The partial dissociation in the effect of OT on defensive responses to predictable and unpredictable shocks can be explained by evidence in rodents that OT facilitates excitatory signaling in a structure that underlies sustained anxiety-like behavior to uncertainty, the BNST, 7, 8 by directly activating corticotrophin releasing factor neurons. Several reasons might explain the failure to detect any AVP effect. The AVP dose may have been too low. Alternatively, OT effects may be mediated by the OT receptor as opposed to AVP receptors (for example, V1a and V1b). Finally, OT and AVP may affect differentially the brainstem pathways that mediate the various components of anxiety, 4 suggesting that startle potentiation is selectively sensitive to OT but not AVP.
Although the finding of increased anxiety following OT administration does not directly inform on OT's pro-social effects, it may explain why OT affects responses to in-group (familiar) and out-group (unfamiliar) members differently. 2, 3 Anxiety is an adaptive defensive response to unpredictable threat. Our data suggest that OT sensitizes such responses in the face of ambiguity/uncertainty, which, when extended to the social domain, would include unfamiliar individuals whose behavior is inherently unpredictable. The hypothesis that OT enhances defensive responses in uncertain social contexts is consistent with findings that OT boosts anti-social behaviors towards unfamiliar individuals. 2, 3 Although in humans OT may strengthen existing social bonds (for example, between relatives/ friends), perhaps reducing anxiety secondarily, it does not create bonds de novo (for example, between strangers), implying that it is less of a 'love' or 'moral' molecule than an 'us and them' molecule C Grillon Benzodiazepines treat anxiety, but can also produce euphoric effects, contributing to abuse. Using perfusion magnetic resonance imaging, we provide the first direct evidence in humans that alprazolam (Xanax) acutely increases perfusion in the nucleus accumbens, a key reward-processing region linked to addiction. Benzodiazepines exert not only therapeutic anxiolytic effects but also undesirable side effects by enhancing GABA signaling through receptors expressed widely in the brain. Benzodiazepine receptors are enriched in human ventral striatum/nucleus accumbens, 1 a critical region for normal and pathological motivational processes. Recent non-human studies demonstrated that benzodiazepines activate accumbens through alpha-1 GABA receptor-mediated disinhibition of mesolimbic dopamine projections to accumbens, 2 as well as through direct effects on alpha-2 GABA receptors. 3 However, there is no direct evidence of benzodiazepine effects on accumbens in humans.
Pharmacological effects on regional brain function are coupled to changes in regional cerebral blood flow (CBF) and can be detected using arterial spin labeled (ASL) perfusion MRI. We used pulsed ASL (PASL) with previously described acquisition and analysis methods 4 to examine the effects of oral alprazolam (1 mg) administered 1 h before MRI in a balanced crossover placebocontrolled double-blind design (see Wolf et al. 5 for details of study procedures, sample and fMRI results; PASL was performed before fMRI). All procedures were performed with written informed consent and Penn Institutional Review Board approval.
Usable PASL data were obtained from 45 of 47 healthy adult subjects including 19 unaffected relatives of patients with schizophrenia. As alprazolam-induced perfusion changes did not differ by family history, subjects were pooled in a combined analysis. To localize the effects of alprazolam on regional brain function, we examined relative CBF changes, normalized by whole brain mean CBF. 6 Alprazolam did not significantly change global CBF, 5 and absolute regional CBF results were qualitatively similar to these normalized results.
A single dose of oral alprazolam increased CBF in accumbens (Figure 1 ), compared with placebo. Furthermore, subjects with higher accumbens perfusion on alprazolam showed faster (r ¼ À 0.35, P ¼ 0.020) and less accurate (r ¼ À 0.30, P ¼ 0.045) responses in a memory task following the perfusion scan. 5 In contrast, CBF was reduced in a cluster spanning posterior thalamus and posterior midbrain. Subjects with lower thalamus perfusion after alprazolam had slower reaction times (r ¼ À 0.31, P ¼ 0.040) with no relationship to accuracy (r ¼ 0.004, P ¼ 0.98). Drug effects in accumbens and thalamus/midbrain were not correlated (r ¼ 0.12, P ¼ 0.43), suggesting they may reflect different aspects of drug action.
These results provide the first direct demonstration in humans of selective benzodiazepine effects on accumbens, consistent with GABAergic activation of the mesolimbic dopamine system. However, identifying the precise neuronal source of this effect requires further investigation (see Supplementary discussion). Anxiolytic effects of benzodiazepines have been linked to reduced amygdala activity. We suggest that increased accumbens perfusion reflects known effects of benzodiazepines including euphoria, disinhibition, impulsivity, risk-taking and addiction. The observed relationship between greater alprazolam-induced accumbens resting perfusion and more impulsive responding in a subsequent cognitive task supports this interpretation. Alprazolam may also have antidepressant effects, 7 and may produce transient benefits on negative symptoms of schizophrenia. 8 Ventral striatum hypofunction is implicated in both depression and negative symptoms, suggesting that increased accumbens perfusion might also be relevant to mechanisms of therapeutic benefit. Future studies can determine whether alprazolam's effect on accumbens perfusion is shared with other benzodiazepine and non-benzodiazepine anxiolytics that vary in abuse potential, and whether this effect predicts treatment responses. , two-tailed cluster Po0.05, minimum voxel activation height Z42.33). Alprazolam (1 mg oral dose) increased CBF in nucleus accumbens (red color bar; right cluster P ¼ 0.002, 184 voxels, peak Z 3.49 at MNI 10,8, À 2; left cluster P ¼ 0.003, 168 voxels, peak Z 2.91 at MNI À 12, 10, À 6). This cluster also extended into white matter of the anterior limb of the internal capsule, the medial border of the ventral putamen and the ventromedial border of the caudate head. In contrast, CBF was reduced by alprazolam in posterior thalamus and midbrain (blue color bar; cluster Po0.001, 1474 voxels, peak Z 3.81 at MNI 6, À 30, À 4). Further details regarding cluster localization, t-tests for treatment effects and exclusion of potential sequence or carryover effects are available in Supplementary Materials. MNI, Montreal Neurological Institute.
